Rheumatology
Psoriatic Arthritis
CASPAR criteria, distinguish PsA patterns, NSAIDs / DMARDs / biologics, treat skin + joints + comorbidities together.
Source: EULAR 2023; GRAPPA 2021
Step 1 of ~3
info
CASPAR Criteria
Inflammatory articular disease (joint, spine, entheseal) + ≥3 points from:
• Current psoriasis (2 points), personal history (1), family history first/second-degree (1).
• Typical psoriatic nail dystrophy (pitting, onycholysis, hyperkeratosis) (1).
• Negative RF (1).
• Dactylitis current or past (1).
• Juxta-articular new bone formation on hand/foot XR (1).
Five patterns (Moll & Wright):
• Asymmetric oligoarthritis (most common).
• Symmetric polyarthritis (RA-like).
• Distal interphalangeal predominant.
• Spondyloarthritis (axial — sacroiliitis, spondylitis).
• Arthritis mutilans (severe deformity).
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Deucravacitinib (TYK2 Inhibitor — Psoriatic Arthritis/Psoriasis) · Selective TYK2 Inhibitor (Allosteric — Regulatory Domain Binding)
- Chlorhexidine gluconate with isopropyl alcohol · Skin antiseptic
- Chlorhexidine with cetrimide · Skin antiseptic / wound cleanser
- Barrier creams and ointments · Topical skin protectant
- Chlorhexidine · Antiseptic / disinfectant (bisbiguanide)
- Cefalexin · First-Generation Cephalosporin — Skin / Soft Tissue / UTI
Pathways
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022
Decision support only. Always apply local guidelines and clinical judgement.